CliffBio
small molecule

UPTRAVI

SELEXIPAG

Loss of exclusivityFebruary 2031latest FDA-listed patent expiry
CompanyActelion →View the full company profile on CliffBio

Drug detail

Brand nameUPTRAVI
Active ingredientSELEXIPAG
Strength1.8MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2021
Marketing statusRX

Listed patents

PatentExpiresType
8791122*PEDFebruary 2031—
9284280*PEDDecember 2030—
8791122August 2030substance, product
9284280June 2030use U-1831
9173881*PEDFebruary 2030—
9173881August 2029use U-1798
7205302*PEDApril 2027—
7205302October 2026substance, product

More from Actelion

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

UPTRAVI patent cliff — loss of exclusivity February 2031 | CliffBio